Cargando…
Durvalumab-Induced Diffuse Alveolar Hemorrhage: An Autopsy Case Report
Durvalumab, a programmed cell death ligand 1 inhibitor, induces various immune-related adverse events (irAEs), including lung injury. However, diffuse alveolar hemorrhage (DAH) is a rare type of lung injury due to immune checkpoint inhibitors. A 76-year-old man with c-stage IIIA squamous cell carcin...
Autores principales: | Kanaoka, Kensuke, Ikebe, Saori, Ihara, Shouichi, Tsuji, Hiromi, Yasuoka, Hironao, Minami, Seigo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383190/ https://www.ncbi.nlm.nih.gov/pubmed/32774259 http://dx.doi.org/10.1159/000507848 |
Ejemplares similares
-
Pulmonary Adenosquamous Cell Carcinoma With Systemic Lymphadenopathy due to Immunoglobulin G4-Related Disease: A Case Report
por: Ikebe, Saori, et al.
Publicado: (2021) -
Pembrolizumab-Induced Meningoencephalitis: A Brain Autopsy Case
por: Minami, Seigo, et al.
Publicado: (2021) -
Rituximab for the Treatment of Anti-glomerular Basement Membrane Disease with Isolated Diffuse Alveolar Hemorrhage
por: Kanaoka, Kensuke, et al.
Publicado: (2022) -
High neutrophils and low lymphocytes percentages in bronchoalveolar lavage fluid are prognostic factors of higher in-hospital mortality in diffuse alveolar hemorrhage
por: Kanaoka, Kensuke, et al.
Publicado: (2021) -
Pembrolizumab-Induced Delayed-Onset Hepatitis
por: Kanaoka, Kensuke, et al.
Publicado: (2020)